Elekta AB stock (SE0000163628): radiotherapy specialist updates investors after latest quarterly results

Elekta AB, the Swedish specialist for radiotherapy and oncology software, has recently updated investors with new quarterly figures and commentary on market conditions in cancer care. The company reported results for the third quarter of its 2024/25 fiscal year on March 7, 2025, highlighting revenue growth, improved profitability and solid order development, according to Elekta investor information as of 03/07/2025. The update came amid ongoing investment in radiotherapy capacity worldwide and continuing normalization after earlier supply chain disruptions, as noted by Reuters as of 03/07/2025.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

Elekta AB: core business model

Elekta AB focuses on solutions for treating cancer and brain disorders, with a core portfolio of linear accelerators, brachytherapy equipment and software that supports planning and delivery of radiation therapy. Hospitals and cancer centers worldwide use its systems to deliver precise tumor irradiation while trying to protect healthy tissue, a key clinical and economic challenge in oncology care, according to Elekta company information as of 02/10/2025.

The company’s business model is built on selling capital equipment such as linear accelerators, followed by long-term service, maintenance and software upgrades. These recurring revenues can help smooth the effects of cycles in capital expenditure and are an important component of profitability, as highlighted in management commentary in the third-quarter 2024/25 results, according to Elekta quarterly report as of 03/07/2025.

Elekta also offers advanced treatment techniques such as stereotactic radiosurgery, which is used for certain brain conditions and small tumors. Its software platforms integrate imaging, treatment planning and workflow management, helping clinicians coordinate care across multidisciplinary teams. This integrated approach is designed to increase utilization of installed systems, which can be a decisive factor in purchasing decisions by hospitals and health systems, as noted by Fierce Biotech medtech coverage as of 01/22/2025.

Main revenue and product drivers for Elekta AB

The largest revenue driver for Elekta AB is the sale and installation of radiotherapy systems, particularly linear accelerators used for external beam radiation therapy. These machines are typically purchased through multi-year procurement cycles, often supported by public health budgets or large private hospital investments. In the third quarter of fiscal 2024/25, Elekta reported that order intake remained solid, supported by demand in both established and emerging markets, according to Elekta quarterly report as of 03/07/2025.

Service and software contracts represent another important revenue stream. Once a system is installed, hospitals typically sign multi-year agreements for maintenance, spare parts and software updates. These contracts can provide recurring income and create long-term customer relationships. Elekta has emphasized growth in software and service, including oncology information systems that help manage patient data and treatment schedules, according to Elekta newsroom as of 11/15/2024.

Innovation also plays a role in Elekta’s revenue mix. The company has developed MRI-guided radiotherapy solutions through its Elekta Unity platform, which aims to improve visualization of tumors during treatment. Adoption of such advanced systems tends to be gradual, as hospitals evaluate clinical benefits, workflow changes and reimbursement conditions, especially in key markets like the United States and Europe. Elekta indicated that advanced offerings continued to gain interest among leading cancer centers, particularly in North America, according to Reuters as of 03/07/2025.

Industry trends and competitive position

The radiotherapy market is shaped by demographic trends, cancer incidence and healthcare investment levels. Global cancer cases are expected to grow over the next decade, creating structural demand for diagnosis and treatment capacity. At the same time, health systems face budget constraints and staffing challenges, which influence purchasing decisions for complex equipment. Industry observers note that vendors must balance advanced features with ease of use and efficiency gains, according to S&P Global healthcare analysis as of 12/09/2024.

Elekta competes globally with other major radiotherapy equipment manufacturers, with competition centered on technology, reliability, service quality and total cost of ownership. In recent years, the company has worked on improving delivery times and resolving earlier supply chain bottlenecks that affected installations. Management reported progress in stabilizing operations and improving margins in the latest quarterly update, while continuing to invest in product development and digital solutions, according to Elekta quarterly report as of 03/07/2025.

Regulatory environments also influence the competitive landscape. Radiotherapy systems and software are subject to rigorous approval processes in markets such as the United States, where the Food and Drug Administration reviews new devices and indications. Meeting regulatory requirements and clinical evidence standards can be resource-intensive but may also create barriers to entry. Elekta has highlighted its continued focus on compliance and quality systems as part of its long-term competitiveness, according to Elekta sustainability report as of 02/10/2025.

Why Elekta AB matters for US investors

Although Elekta AB is headquartered in Sweden and listed on Nasdaq Stockholm, its products are widely used in the United States and other international markets. Radiotherapy capacity and replacement cycles in US cancer centers can influence order intake and revenue composition. For US-based investors, Elekta provides exposure to global oncology equipment demand, including hospitals and treatment centers that serve American patients, according to Elekta global presence overview as of 02/10/2025.

Currency movements between the Swedish krona and the US dollar can also be relevant. Many of Elekta’s sales are denominated in currencies other than SEK, while the reporting currency remains the Swedish krona. Exchange rate fluctuations can therefore affect reported results and margins. US investors who follow the medtech and oncology sectors sometimes compare Elekta with US-listed peers in terms of growth, profitability and innovation focus, according to Bloomberg market data as of 03/10/2025.

Conclusion

Elekta AB remains a focused player in radiotherapy and oncology software, operating in a market supported by long-term demographic trends and rising cancer incidence. The recent quarterly update underlined progress on revenue growth and profitability, while also highlighting the importance of order intake, operational efficiency and innovation in advanced treatment technologies. For US investors, the stock offers exposure to global cancer care infrastructure via a European listing, with potential influences from currency movements, regulatory developments and competitive dynamics. How the company manages its pipeline of new systems, software and service offerings will likely remain central to the investment narrative in the coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.